NMPA · Life Science & Pharma: GxP - AI
Implementation Opinions of NMPA on Artificial Intelligence + Drug Regulation
Final AI · Guidance Last verified: not yet · Source last checked 3 Nov 2026
- Issued by
- NMPA
- Category
- AI
- Sub Category
- Guidance
- Legal weight
- Guidance & Q&A
- Reuse
- Link only
China's plan for how regulators will use AI in their own work on medicines, such as review and inspection. It is aimed at regulators, not companies.
How to read this page
- The line under the title explains in plain words what this item is for. The coloured label beside its status gives its Category, its main subject, and Sub Category, the type of document, in the same colours as the maps.
- Status comes from the latest dated event below, and each event links to its source.
- Lifecycle shows the steps so far, then any expected target. Targets are not facts.
- In plain English is our own summary, not the official text. Where we have read the document in detail, a fuller profile follows, with its context, scope, contents and key points.
- Related shows links to other documents. Select Compare to see two side by side.
Lifecycle
Solid steps have happened. A dashed step is expected, and it is not a fact. Only dated steps in our record appear here.
- Issued by NMPA
In plain English
NMPA policy (GYJZ [2026] No. 6) on using AI in drug regulation, including review, inspection, testing and surveillance. It is aimed at regulators, not manufacturers. Link only.
Summary drafted with AI assistance. Not yet reviewed by the SME Reviewer. Read the official text before acting.
Context and history
NMPA issued these Implementation Opinions (GYJZ [2026] No. 6) on 2 April 2026, and the English text was posted on 20 August 2026. They set out plans for using AI in drug regulation, including review, inspection, testing and surveillance. They build on China's national AI plans. They are aimed at regulators, not manufacturers.
Who and what it applies to
Medical products administrations and NMPA bodies in China. Manufacturers should read them for direction only.
What it contains
- Content
- Goals and tasks for AI in review, supervision, inspection, testing and government services.
Key points
- It is about regulators' use of AI.
- Inspections may increasingly use AI tools.
In practice
General reading, not advice. This is drafted with AI and may not fit your situation. It does not replace the official text, your own quality system or qualified advice, and an inspector may take a different view.
- If you supply China, watch for later rules aimed at industry.
Read from the source document on 1 Nov 2026. This is our own description, not the official text. Check the full dated history in the change log below.
Change log
Key dated events only, not a complete history. Status after is the status once that event happened. Event kinds explained
| Date | Event | Status after | Source |
|---|---|---|---|
| 2 Apr 2026 | Issued by NMPA | Final | Source for Issued by NMPA |
Official source
The official text always prevails over anything on this site.
Summary in our own words. See the official text from NMPA.
Stay updated
Newsletter signup opens at launch.